Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Pazopanib active in von Hippel-Lindau disease neoplasms

Jonasch E et al. Lancet Oncol. 2018 Sep 17. doi: 10.1016/S1470-2045(18)30487-X

Key clinical point: Pazopanib appears efficacious and safe for treating neoplasms associated with von Hippel-Lindau disease.

Major finding: The objective response rate was 42% overall, with response seen in 52% of renal cell carcinomas.

Study details: Single-center, single-arm, open-label, phase 2 trial among 31 adult patients with clinical manifestations of von Hippel-Lindau disease who were treated with pazopanib for at least 24 weeks.

Disclosures: Dr. Jonasch disclosed that he receives research support and honoraria from Novartis. The study was funded by Novartis and by a National Institutes of Health National Cancer Institute core grant.

Read the article.

Citation:

Jonasch E et al. Lancet Oncol. 2018 Sep 17. doi: 10.1016/S1470-2045(18)30487-X